当前位置: 首页 >> 检索结果
5. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
作者: Brian G M Durie.;Antje Hoering.;Muneer H Abidi.;S Vincent Rajkumar.;Joshua Epstein.;Stephen P Kahanic.;Mohan Thakuri.;Frederic Reu.;Christopher M Reynolds.;Rachael Sexton.;Robert Z Orlowski.;Bart Barlogie.;Angela Dispenzieri.
来源: Lancet. 2017年389卷10068期519-527页
Lenalidomide plus dexamethasone is a reference treatment for patients with newly diagnosed myeloma. The combination of the proteasome inhibitor bortezomib with lenalidomide and dexamethasone has shown significant efficacy in the setting of newly diagnosed myeloma. We aimed to study whether the addition of bortezomib to lenalidomide and dexamethasone would improve progression-free survival and provide better response rates in patients with previously untreated multiple myeloma who were not planned for immediate autologous stem-cell transplant.
6. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!).
作者: Ana Maria Henao-Restrepo.;Anton Camacho.;Ira M Longini.;Conall H Watson.;W John Edmunds.;Matthias Egger.;Miles W Carroll.;Natalie E Dean.;Ibrahima Diatta.;Moussa Doumbia.;Bertrand Draguez.;Sophie Duraffour.;Godwin Enwere.;Rebecca Grais.;Stephan Gunther.;Pierre-Stéphane Gsell.;Stefanie Hossmann.;Sara Viksmoen Watle.;Mandy Kader Kondé.;Sakoba Kéïta.;Souleymane Kone.;Eewa Kuisma.;Myron M Levine.;Sema Mandal.;Thomas Mauget.;Gunnstein Norheim.;Ximena Riveros.;Aboubacar Soumah.;Sven Trelle.;Andrea S Vicari.;John-Arne Røttingen.;Marie-Paule Kieny.
来源: Lancet. 2017年389卷10068期505-518页
rVSV-ZEBOV is a recombinant, replication competent vesicular stomatitis virus-based candidate vaccine expressing a surface glycoprotein of Zaire Ebolavirus. We tested the effect of rVSV-ZEBOV in preventing Ebola virus disease in contacts and contacts of contacts of recently confirmed cases in Guinea, west Africa.
8. Adverse events after first, single, mesh and non-mesh surgical procedures for stress urinary incontinence and pelvic organ prolapse in Scotland, 1997-2016: a population-based cohort study.
作者: Joanne R Morling.;David A McAllister.;Wael Agur.;Colin M Fischbacher.;Cathryn M A Glazener.;Karen Guerrero.;Leanne Hopkins.;Rachael Wood.
来源: Lancet. 2017年389卷10069期629-640页
Concerns have been raised about the safety of surgery for stress urinary incontinence and pelvic organ prolapse using transvaginal mesh. We assessed adverse outcomes after first, single mesh procedures and comparable non-mesh procedures.
9. Mesh, graft, or standard repair for women having primary transvaginal anterior or posterior compartment prolapse surgery: two parallel-group, multicentre, randomised, controlled trials (PROSPECT).
作者: Cathryn Ma Glazener.;Suzanne Breeman.;Andrew Elders.;Christine Hemming.;Kevin G Cooper.;Robert M Freeman.;Anthony Rb Smith.;Fiona Reid.;Suzanne Hagen.;Isobel Montgomery.;Mary Kilonzo.;Dwayne Boyers.;Alison McDonald.;Gladys McPherson.;Graeme MacLennan.;John Norrie.; .
来源: Lancet. 2017年389卷10067期381-392页
The use of transvaginal mesh and biological graft material in prolapse surgery is controversial and has led to a number of enquiries into their safety and efficacy. Existing trials of these augmentations are individually too small to be conclusive. We aimed to compare the outcomes of prolapse repair involving either synthetic mesh inlays or biological grafts against standard repair in women.
11. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial.
作者: Firas H El-Khatib.;Courtney Balliro.;Mallory A Hillard.;Kendra L Magyar.;Laya Ekhlaspour.;Manasi Sinha.;Debbie Mondesir.;Aryan Esmaeili.;Celia Hartigan.;Michael J Thompson.;Samir Malkani.;J Paul Lock.;David M Harlan.;Paula Clinton.;Eliana Frank.;Darrell M Wilson.;Daniel DeSalvo.;Lisa Norlander.;Trang Ly.;Bruce A Buckingham.;Jamie Diner.;Milana Dezube.;Laura A Young.;April Goley.;M Sue Kirkman.;John B Buse.;Hui Zheng.;Rajendranath R Selagamsetty.;Edward R Damiano.;Steven J Russell.
来源: Lancet. 2017年389卷10067期369-380页
The safety and effectiveness of a continuous, day-and-night automated glycaemic control system using insulin and glucagon has not been shown in a free-living, home-use setting. We aimed to assess whether bihormonal bionic pancreas initialised only with body mass can safely reduce mean glycaemia and hypoglycaemia in adults with type 1 diabetes who were living at home and participating in their normal daily routines without restrictions on diet or physical activity.
13. Counselling for Alcohol Problems (CAP), a lay counsellor-delivered brief psychological treatment for harmful drinking in men, in primary care in India: a randomised controlled trial.
作者: Abhijit Nadkarni.;Benedict Weobong.;Helen A Weiss.;Jim McCambridge.;Bhargav Bhat.;Basavaraj Katti.;Pratima Murthy.;Michael King.;David McDaid.;A-La Park.;G Terence Wilson.;Betty Kirkwood.;Christopher G Fairburn.;Richard Velleman.;Vikram Patel.
来源: Lancet. 2017年389卷10065期186-195页
Although structured psychological treatments are recommended as first-line interventions for harmful drinking, only a small fraction of people globally receive these treatments because of poor access in routine primary care. We assessed the effectiveness and cost-effectiveness of Counselling for Alcohol Problems (CAP), a brief psychological treatment delivered by lay counsellors to patients with harmful drinking attending routine primary health-care settings.
14. The Healthy Activity Program (HAP), a lay counsellor-delivered brief psychological treatment for severe depression, in primary care in India: a randomised controlled trial.
作者: Vikram Patel.;Benedict Weobong.;Helen A Weiss.;Arpita Anand.;Bhargav Bhat.;Basavraj Katti.;Sona Dimidjian.;Ricardo Araya.;Steve D Hollon.;Michael King.;Lakshmi Vijayakumar.;A-La Park.;David McDaid.;Terry Wilson.;Richard Velleman.;Betty R Kirkwood.;Christopher G Fairburn.
来源: Lancet. 2017年389卷10065期176-185页
Although structured psychological treatments are recommended as first-line interventions for depression, only a small fraction of people globally receive these treatments because of poor access in routine primary care. We assessed the effectiveness and cost-effectiveness of a brief psychological treatment (Healthy Activity Program [HAP]) for delivery by lay counsellors to patients with moderately severe to severe depression in primary health-care settings.
15. Use of MRI in the diagnosis of fetal brain abnormalities in utero (MERIDIAN): a multicentre, prospective cohort study.
作者: Paul D Griffiths.;Michael Bradburn.;Michael J Campbell.;Cindy L Cooper.;Ruth Graham.;Deborah Jarvis.;Mark D Kilby.;Gerald Mason.;Cara Mooney.;Stephen C Robson.;Allan Wailoo.; .
来源: Lancet. 2017年389卷10068期538-546页
In-utero MRI (iuMRI) has shown promise as an adjunct to ultrasound but the comparative diagnostic performance has been poorly defined. We aimed to assess whether the diagnostic accuracy and confidence of the prenatal diagnosis of fetal brain abnormalities is improved with iuMRI and assess the clinical impact and patient acceptability of iuMRI.
19. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
作者: Achim Rittmeyer.;Fabrice Barlesi.;Daniel Waterkamp.;Keunchil Park.;Fortunato Ciardiello.;Joachim von Pawel.;Shirish M Gadgeel.;Toyoaki Hida.;Dariusz M Kowalski.;Manuel Cobo Dols.;Diego L Cortinovis.;Joseph Leach.;Jonathan Polikoff.;Carlos Barrios.;Fairooz Kabbinavar.;Osvaldo Arén Frontera.;Filippo De Marinis.;Hande Turna.;Jong-Seok Lee.;Marcus Ballinger.;Marcin Kowanetz.;Pei He.;Daniel S Chen.;Alan Sandler.;David R Gandara.; .
来源: Lancet. 2017年389卷10066期255-265页
Atezolizumab is a humanised antiprogrammed death-ligand 1 (PD-L1) monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-1) and PD-L1 and B7-1 interactions, reinvigorating anticancer immunity. We assessed its efficacy and safety versus docetaxel in previously treated patients with non-small-cell lung cancer.
20. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
作者: Arjun V Balar.;Matthew D Galsky.;Jonathan E Rosenberg.;Thomas Powles.;Daniel P Petrylak.;Joaquim Bellmunt.;Yohann Loriot.;Andrea Necchi.;Jean Hoffman-Censits.;Jose Luis Perez-Gracia.;Nancy A Dawson.;Michiel S van der Heijden.;Robert Dreicer.;Sandy Srinivas.;Margitta M Retz.;Richard W Joseph.;Alexandra Drakaki.;Ulka N Vaishampayan.;Srikala S Sridhar.;David I Quinn.;Ignacio Durán.;David R Shaffer.;Bernhard J Eigl.;Petros D Grivas.;Evan Y Yu.;Shi Li.;Edward E Kadel.;Zachary Boyd.;Richard Bourgon.;Priti S Hegde.;Sanjeev Mariathasan.;AnnChristine Thåström.;Oyewale O Abidoye.;Gregg D Fine.;Dean F Bajorin.; .
来源: Lancet. 2017年389卷10064期67-76页
First-line chemotherapy for patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma is associated with short response duration, poor survival, and high toxicity. This study assessed atezolizumab (anti-programmed death-ligand 1 [PD-L1]) as treatment for metastatic urothelial cancer in cisplatin-ineligible patients.
|